Cargando…

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematological diseases and a high risk for transformation to acute myeloid leukemia (AML). The identification of key genetic alterations in MDS has enhanced our understanding of the pathogenesis and evolution. In recent years, it has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaoying, Yang, Xingcheng, Ma, Ling, Zhang, Yicheng, Wei, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399277/ https://www.ncbi.nlm.nih.gov/pubmed/37547364 http://dx.doi.org/10.1177/20406207231183330

Ejemplares similares

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
por: Yang, Xingcheng, et al.
Publicado: (2022)

P712: SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME
por: Yang, Xingcheng, et al.
Publicado: (2023)

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
por: Comont, Thibault, et al.
Publicado: (2021)

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
por: Peng, Xiaohuan, et al.
Publicado: (2022)

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome
por: Lee, Paul, et al.
Publicado: (2021)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Immune Mechanisms in Myelodysplastic Syndrome
por: Glenthøj, Andreas, et al.
Publicado: (2016)

Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
por: Park, Hee Sue, et al.
Publicado: (2017)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy
por: Gill, Harinder, et al.
Publicado: (2016)

Emerging Therapies for the Myelodysplastic Syndromes
por: Canaani, Jonathan
Publicado: (2019)

Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
por: Pagliuca, Simona, et al.
Publicado: (2021)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Summary of animal models of myelodysplastic syndrome
por: Li, Weisha, et al.
Publicado: (2021)

Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies
por: Harada, Hironori, et al.
Publicado: (2015)

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Gallazzi, Marco, et al.
Publicado: (2022)

Infections in Myelodysplastic Syndrome in Relation to Stage and Therapy
por: Leone, Giuseppe, et al.
Publicado: (2018)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
por: Chokr, Nora, et al.
Publicado: (2018)

Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
por: Cassanello, Giulio, et al.
Publicado: (2022)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021)

Targeting age-related inflammation in myelodysplastic syndromes
por: Mei, Yang, et al.
Publicado: (2018)

Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy
por: Bond, Danielle R., et al.
Publicado: (2020)

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool
por: Kalinkova, Lenka, et al.
Publicado: (2022)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Hereditary Predispositions to Myelodysplastic Syndrome
por: Bannon, Sarah A., et al.
Publicado: (2016)

Prognostic Markers of Myelodysplastic Syndromes
por: Veryaskina, Yuliya Andreevna, et al.
Publicado: (2020)

Genetic basis of myelodysplastic syndromes
por: OGAWA, Seishi
Publicado: (2020)

Myelodysplastic Syndrome: Diagnosis and Screening
por: Tria, Francisco P., et al.
Publicado: (2022)

The Mesenchymal Niche in Myelodysplastic Syndromes
por: Friedrich, Chloé, et al.
Publicado: (2022)

New targeted therapies in myelodysplastic syndrome: the role of farnesyltransferase and proteasome inhibitors
por: Gonçalves, A Cristina, et al.
Publicado: (2010)

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
por: Komrokji, Rami, et al.
Publicado: (2022)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_pjdv9mphkbe8ulhibvrbehb2f4